Human Platelet Lysate Market

Rising demand for regenerative medicine therapies and stem cell research drives the Human Platelet Lysate Market.

Human Platelet Lysate Market by Type (Heparin-free Platelet Lysate and Human Platelet Lysate with Heparin)

Report ID: PMRREP16789

Number of Pages: 195

Format: PPT*, PDF, EXCEL

Industry: Healthcare

Published Date: March-2023

Report Price


Buy Now

Human Platelet Lysate Market Outlook (2023 to 2033)

The Global revenue from the Human Platelet Lysate Market was around US$ 52.04 Million in 2022, with the global market expected to grow at a CAGR of 3.4% to reach a valuation of around US$ 75.18 Million by the end of 2033.

Market Size (2023)

US$ 54.01 Million

Projected Market Value (2033)

US$ 75.18 Million

Global Market Growth Rate (2023 to 2033)

3.4% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, heparin-free platelet lysates held a market share of around 51.0% in the global market, in 2022. Overall, human platelet lysate market sales account for around 2.6% of revenue share in the global growth factor market, which was valued at around US$ 1.96 Billion in 2022.

Sample Report

Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get Report Sample

Sales Analysis of Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 3.3% in the last 8 years from 2014 to 2022.

Fetal bovine serum can be replaced by human platelet lysates (HPL), which are produced from human mesenchymal stem cells (FBS). The use of human platelet lysates is growing as a result of the substitution of FBS, which reduces the risk of bovine prion and virus contamination and may potentially bring a new therapeutic challenge in the field of stem cell therapy.

Numerous experimental and clinical research projects have benefited from the development of human platelet lysates. Functional capacities are unaffected by human platelet lysates. Human blood-derived substances such as plasma, serum, umbilical cord blood serum, and platelet derivatives such platelet lysates can be used instead of FBS.

The market for human platelet lysates is anticipated to expand due to the numerous uses of these products, including the creation, production, and research of breakthrough pharmaceutical and technological therapies.

The global market is likely to show significant growth over the coming years at a CAGR of 3.4% and reach a global market size of US$ 75.18 Million by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Growing Demand for Tissue Repair

Demand for tissue restoration devices is anticipated to rise as chronic wounds become more common. Human platelet lysate is crucial for the repair of damaged tissue and the healing of wounds. It is anticipated that rising burn cases and traffic accidents will drive up demand for human platelet lysate. The market for human platelet lysate may become more popular as tissue repair products' demand rises.

  • Collaboration on projects like Cancer MoonShot 2020 among the pharma industry, academic oncology, government, and scientific communities gives researchers access to the testing materials they need, which boosts the life science industry's commercial success.

The availability of technical resources and a broader knowledge base through research collaborations often improve the standard and success rates of research, resulting in the development of more new treatments. The market for human lysate has grown significantly as a result of the initiatives done by researchers to develop various medicines for the treatment of disease. It is anticipated that rising research activities, particularly in developed countries, will fuel market expansion.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

Lack of Awareness and Access to Alternative Products.

One of the biggest barriers to the market for human platelet lysate is lack of awareness. Additionally, there are alternatives available, which is predicted to impede market expansion. Fetal bovine serum is no longer the standard serum supplement used in Adipose-Derived Stromal Cell (ASC) growth. The goal of research has been to find xeno-free or human blood-derived substitutes. Human serum, platelet-rich plasma, platelet-poor plasma, platelet lysate, and other products generated from human blood are among the options.

A fierce price competition exists in the human platelet lysate market since low-cost products are offered by regional producers and academic institutions. The companies are also under pressure from the market's dominance by leading, international manufacturers of human platelet lysate and its huge sales volume. Small manufacturing companies are under pressure because of the dominant companies' negotiating muscle. Therefore, it is anticipated that restrictions on pricing due to competition will impede the market's overall growth.

Country-wise Insights

Why is the United States Market Booming?

“Increasing Prevalence of Nerve Injuries”

The United States accounted for around 90.1% market share in the North America market in 2022. Increasing cases of nerve injury in the region is responsible for the market growth.

  • For instance, according to the article published by Medical University of South Carolina in 2019, the number of nerve injury cases were around 5244 and the total number of traumatic injuries for upper extremities were around 1.58 million.

The advantages of steroid injections are provided by platelet lysate (PL), but without the negative effects of weakened connective tissue or a lowered immunological response. This gives an anti-inflammatory effect, increasing the demand of it during nerve injury. This factor is responsible for the segment growth.

Will the Germany Be a Lucrative Market for Human platelet lysate?

“Increasing Geriatric Population”

The Germany market held around 29.4% market share of the Europe market in 2022. Those who are elderly and have multiple comorbidities are frequently affected by neuropathic pain brought on by a sensorimotor system lesion or disease. Additionally, older patients frequently receive multiple medications, are hospitalised, and receive care in nursing homes, all of which increase the risk of drug interactions and recurrent hospitalisation.

In order to improve the quality of life for the patients and, when applicable, their families, neuropathic pain in the elderly must be addressed using a multifaceted strategy that incorporates a number of medical, social, and psychological professionals. Increasing geriatric population is main factor for the regional dominance, resulting in rising cases of neuropathic disorder, which increases the demand for human platelet lysate.

How is China Emerging as a Prominent Market?

“Increasing Prevalence of Osteoarthritis”

China held a market share of about 34.3% of the East Asia market in 2022. The primary factor driving the regional dominance is increasing prevalence of osteoarthritis in the region. A prevalent chronic degenerative joint condition known as knee osteoarthritis (KOA) typically causes knee pain, stiffness, functional limitations, and may even result in disability.

  • For instance, according to the article published by International Journal of Environmental Research and Public Health, in 2021, in China, there were 249,000 total knee arthroplasty procedures performed in 2018, with an approximate cost of 12.948 billion yuan. Therefore, knee osteoarthritis carries a significant disease burden.

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Absence of Any Additives”

The heparin-free platelet lysates segment held around 51.0% share of the total market in 2022. An anticoagulant, heparin works to stop blood clots from forming. Blood clots brought on by a few diseases or medical procedures are prevented or treated using heparin. Human blood platelet lysate that does not require the addition of heparin is known as heparin free platelet lysate. Heparin must be added to human platelet lysate in order for it to function properly.

Human platelet lysate without heparin is a preparation that has all the components needed to extract proteins and nucleic acids from human blood cells. Preservatives, antibiotics, or any other additives are not being added to the product. To ensure optimal yield with the least amount of input materials, it is created utilising cutting-edge technology. This factors are responsible for the segment growth.

Which Application is Driving Demand within the Global Market?

“Treatment of Several Diseases”

The clinical use segment held around 93.8% share of the total market in 2022. Alopecia, oral mucositis, radicular discomfort, osteoarthritis, and abnormalities of the cartilage and tendons can all be treated using platelet lysate, a solution rich in growth factors, proteins, cytokines, and chemokines that are essential to healing processes.

Orthobiologics, particularly cell-based therapies using mesenchymal stem cells (MSCs), are being used more frequently to treat musculoskeletal injuries, which has increased the demand for explanations (or elucidations) of the functions of blood components. In addition to primary haemostasis, platelets are crucial for wound healing and tissue regeneration. This factors are supposed to drive the segment growth.

Which End User Propels the Global Sales in the Market?

“Basic Research Conducted in Academic and Research Institutes”

The academic and research institute segment held a share of about 65.0% in 2022, within the global market. Academic research centers have concentrated on cutting-edge basic research, including applied research when governmental or commercial enterprises desire to pursue development initiatives in more affordable methods. The significant number of basic researches are still conducted in academic institutions, since companies’ priorities bringing profitable products to market.

In the United States, academic institutions conduct 56% of basic research, while the sector conducts 61% of applied research and 87% of development, according to a 2012 report from the National Science Foundation. Academic research laboratories continue to be the most dependable organization to carry out fundamental research programs due to their extensive scientific and technological capabilities.

Competition Landscape

Leading players active within the human platelet lysate market globally are actively seeking research-based collaborations in the field of healthcare as a key strategy.

Some key instances of development include:

  • In February 2020, Aimmune Therapeutics, Inc. announced an additional investment of $200 million from Nestlé Health Science towards development of new therapies in regards to food allergies.
  • In July 2020, The Anergis entered into a research collaboration with Virometix, to analyze synthetic virus like particles for ultra-fast Human platelet lysate

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the human platelet lysate market, which are available in the full report.

Human platelet lysate Industry Report Scop



Forecast Period

2023 to 2033

Historical Data Available for

2014 to 2022

Market Analysis

USD Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Key Companies Covered

  • Merck KGaA
  • Compass Biomedical Inc.
  • Macopharma SA
  • Cook Medical (Cook Regentec)
  • Mill Creek Life Sciences Llc.
  • Stemcell Technologies Inc.
  • Zen-Bio, Inc.
  • Sclavo Diagnostics International Srl.
  • Life Science Group Limited (Life Science Production)
  • Trinova Biochem GmbH

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Human Platelet Lysate Industry Research


  • Heparin-free Platelet Lysate
  • Human Platelet Lysate with Heparin


  • Research Use
  • Clinical Use

End User:

  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Others


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

For report customisation and delivery information contact our sales representative.

Companies Covered in This Report

  • Merck KGaA
  • Compass Biomedical Inc.
  • Macopharma SA
  • Cook Medical (Cook Regentec)
  • Mill Creek Life Sciences Llc.
  • Stemcell Technologies Inc.
  • Zen-Bio, Inc.
  • Sclavo Diagnostics International Srl.
  • Life Science Group Limited (Life Science Production)
  • Trinova Biochem GmbH

Frequently Asked Questions

The global market is currently valued at around US$ 52.04 Million in 2022.

The global market estimates for 2023 is around US$ 54.0 Million.

The global market is set to reach valuation of US$ 75.2 Million by the end of 2033.

Sales of the market are set to witness growth at a CAGR of 3.4% between 2023 and 2033.

Demand for the global market increased at a 3.3% CAGR from 2014 to 2022.

The U.S., Germany, the U.K., France, and Brazil account for most demand within the market, currently holding around 59.5% market share.

The U.S. accounts for around 90.1% share of the North American market in 2022.

The China market held a share of about 34.3% in the East Asia human platelet lysate market in 2022.

The Germany market held around 29.4% market share of the Europe market in 2022.

Merck KgaA, Compass Biomedical Inc., Macopharma SA, Cook Medical (Cook Regentec), Mill Creek Life Sciences LLC, Stemcell Technologies Inc., Zen-Bio, Inc., Sclavo Diagnostics International Srl, Life Science Group Limited (Life Science Production) and Trinova Biochem GmbH are the key players active within this space.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate